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Prospective data on childhood tuberculosis (TB) incidence 
and case detection rates (CDRs) are scant, and the pre-
ventable burden of childhood TB has not been measured 
in prospective studies. We investigated 2,042 children (<15 
years of age) with suspected TB by using enhanced sur-
veillance and linked hospital, demographic, notification, 
and verbal autopsy data to estimate the incidence, CDR, 
risk factors, and preventable burden of TB among children 
in Kenya. Estimated TB incidence was 53 cases/100,000 
children/year locally and 95 cases/100,000 children/year 
nationally. The estimated CDR was 0.20–0.35. Among chil-
dren <5 years of age, 49% of cases were attributable to 
a known household contact with TB. This study provides 
much needed empiric data on TB CDRs in children to inform 
national and global incidence estimates. Moreover, our find-
ings indicate that nearly half of TB cases in young children 
might be prevented by implementing existing guidelines for 
TB contact tracing and chemoprophylaxis.
Substantial progress has been made in the fight against tuberculosis (TB); however, new approaches are need-
ed to achieve the current target set by the World Health 
Organization (WHO) to reduce TB incidence to 90% of 
2016 levels by 2035 (1). A key element of WHO’s End TB 
Strategy is the prioritization of preventive treatment (2). 
However, the preventable burden of childhood TB has not 
been quantified in prospective epidemiologic studies, and 
globally, only an estimated 7% of eligible children received 
isoniazid chemoprophylaxis in 2015 (1).
Diagnosis of TB is more challenging in children than 
in adults (3). In low-resource settings, where TB burden is 
highest, diagnosis often relies on poorly validated clinical 
algorithms (4). As a result, adequate surveillance data are 
lacking, and published estimates of the global childhood 
TB burden vary widely (1,5–11). High-quality prospective 
data on the TB burden and case detection rate (CDR) in 
children are recognized priorities (8,11,12), and popula-
tion-level data showing the preventable burden of child-
hood TB might reinforce the public health case for chemo-
prophylaxis in children. We designed the Kilifi Improving 
Diagnosis and Surveillance of Childhood TB (KIDS TB) 
Study to estimate the incidence, CDR, risk factors, and pre-
ventable burden of childhood TB in Kenya.
Methods
Study Sites
The study took place at Coast Provincial General Hospital 
(CPGH) and Kilifi County Hospital (KCH) in Coast Prov-
ince, Kenya. CPGH provides primary and secondary care to 
the city of Mombasa and tertiary services for Coast Province. 
KCH is nested within the Kilifi Health and Demographic 
Surveillance System (KHDSS) (13), which covers a pre-
dominantly rural area of 891 km2 that in March 2011 was 
home to 261,919 residents in 29,970 households; two thirds 
of pediatric admissions to KCH during the study period were 
derived from this system. Three other health facilities in the 
KHDSS provide TB smear microscopy; 12 clinics are desig-
nated TB treatment centers (Figure 1). Because of resource 
constraints, contact tracing was not routine and isoniazid 
chemoprophylaxis not available at the time of the study, de-
spite the inclusion of these steps in national TB guidelines.
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Participants
We established a system of enhanced passive and active 
childhood TB surveillance. In the passive case–detection 
arm, we prospectively recruited all children <15 years of 
age who were seen at KCH or CPGH during August 2009–
July 2011 for an unexplained persistent cough for >2 weeks, 
pneumonia not responding to antibiotics, unexplained fe-
ver for >2 weeks, unexplained progressive weight loss or 
failure to thrive for >4 weeks, close contact with a person 
with TB, or clinical suspicion of TB for any other reason. 
Study clinicians and clinicians from the hospital and sur-
rounding clinics were trained in the symptoms and signs 
of a range of TB presentations (online Technical Appendix 
Table 1, https://wwwnc.cdc.gov/EID/article/24/3/17-0785-
Techapp1.pdf). We excluded children with an established 
alternative diagnosis that explained all the clinical features 
as well as children already on TB treatment for >2 weeks 
at presentation. In the active case–detection arm, we re-
cruited KHDSS-resident children <5 years of age sharing 
a household with persons with new cases of smear-positive 
pulmonary TB.
Clinical Procedures
All children underwent a similar structured history and ex-
amination, chest radiography, and tuberculin skin testing 
according to WHO guidelines (14) (online Technical Ap-
pendix). Children who were able to expectorate provided 
up to 3 spontaneous sputum samples. Sputum induction was 
performed on the remainder (14). Further investigations 
including extrapulmonary or repeat sputum sampling were 
performed at the discretion of the clinical team caring for the 
patient. Provider-initiated testing and counseling for HIV 
was performed according to national guidelines.
We classified children as having confirmed TB, highly 
probable TB, possible TB, or not TB (TB excluded) ac-
cording to clinical, radiologic, and microbiological find-
ings, based closely on stringent published definitions (on-
line Technical Appendix Table 2) (15,16). For comparison, 
we also applied other published clinical definitions to our 
dataset (online Technical Appendix). Treatment protocols 
followed national guidelines. Children were followed up 
for 6 months or until a diagnosis of TB could be confi-
dently excluded.
Laboratory Methods
Acid-fast bacilli microscopy and mycobacterial culture us-
ing the BACTEC MGIT system (BD Diagnostics, Sparks, 
MD, USA) were performed according to standard pro-
tocols (17). Positive cultures were further characterized 
using the BD MGIT TBc Identification Test (BD Diag-
nostics) and Hain Genotype line probe assays (Hain Life-
science GmbH, Nehren, Germany), including isoniazid 
and rifampin drug-susceptibility testing. We performed 
the Xpert MTB/RIF assay version G4 (Cepheid, Sunny-
vale, CA, USA) at the end of the study on specimens from 
all children treated for confirmed, highly probable, or pos-
sible TB as well as from children for whom a TB diagnosis 
had been excluded. Laboratory procedures were externally 
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Figure 1. Kilifi District and the 
Kilifi Health and Demographic 
Surveillance Survey area 
(darker gray shading), showing 
administrative districts, Kilifi County 
Hospital (black square), and other 
tuberculosis treatment facilities 
(white squares), Kenya, 2010.
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monitored using the United Kingdom National External 
Quality Assessment Service’s quality-assurance scheme 
(http://ukneqas.org.uk).
Statistical Analysis
Incidence Estimates
We used clinical data from KCH and event data from 
KHDSS to compile for every KHDSS-resident child a se-
ries of chronological time-span records representing the pe-
riods between consecutive birth, migration, enumeration, 
hospital presentation, or death events during the study pe-
riod. We split these periods of observation by age category 
and estimated crude TB incidence rates as the total number 
of new TB cases identified (by both active and passive case 
detection) divided by the total person-years of observation 
in each age stratum. We compared estimates generated 
using the study case definitions with incidence estimates 
derived by applying other published clinical definitions of 
childhood TB to our dataset (online Technical Appendix).
Estimating the CDR
Crude incidence estimates assume all incident cases among 
KHDSS residents are captured by the study; however, hos-
pital-based surveillance of childhood illnesses is known to 
be insensitive in this setting (18–20). We defined the CDR 
as the proportion of KHDSS-resident TB cases captured by 
the study. Because the actual number of children with TB 
is unknown, we used 3 different methods to estimate the 
CDR independently (detailed description in online Techni-
cal Appendix).
TB Notification Data
We linked clinical data with National Tuberculosis Pro-
gramme notification data and KHDSS census data. We es-
timated the CDR as 1) the proportion of KHDSS-resident 
smear-positive childhood TB cases reported to the National 
Tuberculosis Programme that were captured by passive 
case detection at KCH, and 2) the proportion of children’s 
household contacts of new smear-positive pulmonary TB 
cases captured by active contact tracing.
Hospital-Based Mortality Surveillance
We linked KHDSS vital status data with KCH admission 
data. We then calculated the proportion of all childhood 
deaths in the KHDSS area captured at KCH during the 
study period.
Verbal Autopsy
By using disease-specific mortality data from a contem-
poraneous verbal autopsy study of all deaths within the 
KHDSS (21), we estimated the proportion of childhood 
TB deaths captured by our study. Because the number of 
child TB cases diagnosed by verbal autopsy is small and 
healthcare-seeking behavior is usually determined by clini-
cal features rather than diagnosis per se (20,22), we also 
estimated the CDR as the proportion of children who died 
having clinical features of suspected TB that were captured 
by the study.
To derive the most conservative estimates of the actual 
annual incidence of childhood TB, we divided crude inci-
dence rates by the highest CDR estimate. We modeled the 
likely number of incident confirmed or highly probable TB 
(CHPTB) cases among children nationally by multiplying 
the total number of adult cases reported in Kenya in 2010 
(23) by the ratio of child-to-adult cases in the KHDSS, as-
suming a similar ratio and adult CDR nationally. We then 
used denominator population data from the national census 
(24) to estimate the national incidence of childhood TB.
Risk Factors for Childhood TB
We explored risk factors for childhood TB in a nested 
case–control analysis of children with CHPTB (cases) and 
children for whom TB was excluded (controls). To mitigate 
ascertainment bias in analysis of TB contact history, we ex-
cluded the small minority of children identified through ac-
tive contact tracing. For each association, we derived crude 
odds ratios (ORs) and 95% CIs. We then included in a mul-
tivariable logistic regression model those variables with at 
least a weak association with TB in the univariable analysis 
(likelihood ratio test; p<0.1) and presented adjusted ORs 
and 95% CIs.
By using the number of KHDSS-resident adult cases 
reported to the National Tuberculosis Programme during 
the study period and the mean number of close contacts 
<5 years of age per case (25), we estimated the prevalence 
of household exposure to a person with confirmed TB 
among KHDSS-resident children <5 years of age. Using 
the contact status of CHPTB cases detected in the study, 
the child years at risk derived from the KHDSS census, and 
the exposure prevalence, we estimated the incidence of TB 
among contacts and noncontacts. The population attribut-
able fraction for contact with a person with confirmed TB 
was calculated from the ensuing incidence rate ratio (IRR) 
and the exposure prevalence (p) by calculating p(IRR − 
1)/1 + p(IRR − 1) (online Technical Appendix).
Results
We identified 2,183 children with suspected TB during the 
study period and summarized patient enrollment and diag-
nostic assignments (Figure 2). We excluded 141 (6%) chil-
dren who died, were discharged, or were lost to follow-up 
before their diagnostic workups, including specimen collec-
tion for mycobacterial culture, could be completed (Figure 
2). We summarized baseline clinical characteristics of the 
remaining 2,042 children included in the analyses (Table 1).
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Crude Incidence Estimates
We determined crude, hospital-based, age-specific inci-
dence rates based on the study definitions (Table 2). The in-
cidence of all childhood TB was 30.2 (95% CI 23.6–38.0) 
cases/100,000 children/year. The incidence of CHPTB was 
18.4 (95% CI 13.4–24.7) cases/100,000 children/year; this 
estimate was very similar to that derived by retrospectively 
applying to our data consensus definitions of definite or 
probable TB that were published after completion of our 
study (26) (20.5 [95% CI 15.2–27.1]/100,000/year). Both 
figures are at the lower end of the range of estimates de-
rived using published clinical definitions, which vary >30-
fold (2.9–91.7/100,000/year) (Table 3).
CDR and Adjusted Incidence Estimates
CDR estimates derived using TB notifications, KHDSS 
census data, and verbal autopsy ranged from 0.2 to 0.35 
(Table 4), substantially lower than the estimated CDR of 
0.82 for adults in Kenya (41). Hospital-based mortality sur-
veillance provided the largest and most precise estimate of 
the CDR (0.35 [95% CI 0.31–0.40]), so we used this to 
derive the most conservative estimates of the actual com-
munity incidence of childhood TB (Table 5). After adjust-
ment for CDR, the incidence of CHPTB and all TB among 
children in the KHDSS was 53 (95% CI 38–71) and 86 
(95% CI 67–109) cases/100,000/year, respectively.
Implications for the National Incidence of Childhood TB
During August 2009–July 2011, a total of 678 new cases of 
adult TB were reported to the National Tuberculosis Pro-
gramme, and an estimated 126 new CHPTB cases were re-
ported in children (Table 5) among KHDSS residents. Na-
tionally 89,883 adult and 5,721 child TB cases were reported 
in 2010 (41) among a population that includes ≈17.6 million 
children <15 years of age (24). Applying the ratio of adult-to-
child TB cases in the KHDSS to the national caseload yields 
an estimated 16,704 new CHPTB cases among children <15 
years of age nationally in 2010, suggesting a national child-
hood TB CDR of 29% and incidence of 95 cases/100,000 
children/year (online Technical Appendix Table 3).
Risk Factors for Childhood TB
We summarized associations of CHPTB and important 
putative risk factors (Table 6). A history of known close 
TB contact at presentation was strongly associated with 
CHPTB, with an effect gradient according to the contacts’ 
smear status, proximity, relationship, and number (online 
Technical Appendix Table 4). No child case-patients with 
a close TB contact had received isoniazid chemoprophy-
laxis. We observed a weaker association with HIV and in 
young children with severe malnutrition but no association 
between the presence of a bacillus Calmette-Guérin (BCG) 
vaccination scar and TB, although power to detect an effect 
was low because of the small proportion of children with-
out a BCG vaccination scar.
Preventable TB Burden among Child  
Household TB Contacts
Among KHDSS-resident children <5 years of age, an es-
timated 1,259 were close contacts of adults with new TB 
cases reported during the study period. The incidence of 
CHPTB was 596 cases/100,000/year among children with 
a close TB contact and 17 cases/100,000/year among those 
without a close TB contact, yielding a 49% population at-
tributable fraction for having a recent and known TB con-
tact (online Technical Appendix Table 5).
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Figure 2. TB patient enrollment 
and disease classifications, 
Kilifi Health and Demographic 
Surveillance Survey, Kenya, 
August 2009–July 2011. A 
total of 141 children were not 
investigated (27 died, 40 were 
discharged, 3 were transferred, 
1 self-discharged before workup 
completed, 30 defaulted outpatient 
follow-up, 40 had no reason 
documented). At KDH, 108/1,042 
(10%) children investigated were 
identified through active contact 
tracing (2 confirmed TB, 4 highly 
probable TB, 87 not TB, 15 
not classifiable). CPGH, Coast 
Provincial General Hospital; KDH, 
Kilifi District Hospital; KHDSS, 
Kilifi Health and Demographic 
Surveillance Survey;  
TB, tuberculosis.
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Discussion
This study provides rare prospective empiric data on the 
TB incidence and CDR among children <15 years of age 
in Kenya, a country with a high TB burden, and is one 
of few prospective incidence studies globally (3). This 
community-based study was nested in a demographic 
surveillance survey, underpinned by enhanced active and 
passive surveillance, mycobacterial culture facilities, and 
linked hospital, demographic, notification, and verbal au-
topsy data. We used a hierarchical diagnostic classifica-
tion in keeping with recommendations for childhood TB 
surveillance and research (26,35). A comprehensive algo-
rithm of clinical, radiologic, and laboratory investigations 
combined with careful follow-up of children enrolled in 
the KIDS TB Study ensured diagnostic classifications were 
optimized within the limitations of currently available 
diagnostic tools.
Although the diagnosis of confirmed TB has the high-
est specificity, the poor sensitivity of mycobacterial culture 
for childhood TB diagnosis means that incidence estimates 
based only on confirmed cases will underestimate the ac-
tual disease burden. Conversely, including possible TB 
cases in the numerator might overestimate incidence. Most 
children in the highly probable TB group probably did have 
TB, given the stringent diagnostic criteria, and although the 
sensitivity of this classification is not perfect, it probably 
captured many of the actual cases of active TB for which 
culture confirmation was not obtained. We therefore used a 
combination of confirmed or highly probable TB (CHPTB) 
as the measure most likely to optimize sensitivity and spec-
ificity for estimation of childhood TB incidence.
Compared with estimates based on published clinical 
definitions, our measure of CHPTB incidence is among 
the most conservative, similar to the estimate obtained by 
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Table 1. Baseline characteristics of children with and without TB examined at Kilifi County Hospital and Coast Provincial General 
Hospital, Kenya, August 2009–July 2011* 
Characteristic 
Confirmed TB, 
n = 73 
Highly probable 
TB, n = 83 
Treated for 
possible TB,  
n = 141 
Not TB/TB 
excluded,  
n = 1,320 
Not classifiable, 
n = 425 
Case ascertainment      
 Passive case detection 71 (97) 79 (95) 141 (100) 1,237 (94) 410 (96) 
 Active case detection (contact tracing) 2 (3) 4 (5) 0 (0) 83 (6) 15 (4) 
Patient demographics      
 Median age (interquartile range), mo 52 (16–114) 32 (13–70) 17 (10–64) 17 (10–41) 17 (9–44) 
  0–4 y 38 (55) 59 (71) 99 (70) 1,119 (85) 345 (81) 
  5–9 y 17 (25) 15 (18) 27 (19) 140 (11) 56 (13) 
  10–14 y 18 (25) 9 (11) 15 (11) 61 (4) 24 (6) 
 Sex      
  M 39 (53) 43 (52) 70 (50) 696 (53) 224 (53) 
  F 32 (47) 40 (48) 71 (50) 624 (47) 201 (47) 
Risk factors for TB           
 HIV infected 17 (23) 21 (25) 42 (30) 160 (12) 112 (26) 
 Severely malnourished 30 (41) 37 (45) 58 (41) 457 (35) 162 (38) 
 BCG vaccination scar 65 (89) 86 (71) 128 (91) 1,172 (89) 338 (80) 
 Close TB contact 36 (49) 33 (40) 27 (19) 246 (19) 78 (18) 
Clinical features of suspected TB           
 Cough >2 wks 48 (66) 48 (58) 95 (67) 572 (43) 225 (53) 
 Fever >2 wks 45 (62) 30 (36) 92 (65) 502 (38) 196 (46) 
 Weight loss or failure to thrive >4 wks 42 (58) 39 (47) 77 (55) 575 (44) 208 (49) 
 Pneumonia not responding to 1st-line ABX 27 (37) 25 (30) 42 (30) 308 (23) 159 (37) 
TB clinical syndrome           
 Smear-positive pulmonary TB 20 (27) 4 (5) 0 NA NA 
 Smear-negative pulmonary TB 40 (55) 69 (83) 108 (77) NA NA 
 All pulmonary TB† 60 (82) 73 (88) 108 (77) NA NA 
 Extrapulmonary TB† 30 (41) 17 (20) 46 (33) NA NA 
  Miliary TB 6 (8) 3 (4) 5 (4) NA NA 
  TB meningitis 8 (11) 2 (2) 12 (9) NA NA 
  Pleural TB 6 (9) 2 (2) 7 (5) NA NA 
  TB lymphadenitis 6 (8) 6 (7) 6 (4) NA NA 
  Osteoarticular TB 2 (3) 3 (4) 1 (1) NA NA 
  Abdominal TB 9 (12) 2 (2) 10 (7) NA NA 
  Persistent fever without a focus 0 1 (1) 13 (9) NA NA 
Drug resistance           
 Isoniazid monoresistance 0 NA NA NA NA 
 Multidrug-resistant TB 1 (1.4) NA NA NA NA 
*Values are no. (%) unless otherwise indicated. ABX, antibiotics; BCG, bacillus Calmette-Guérin; NA, not applicable; TB, tuberculosis. 
†Some children had >1 focus of infection, including some with pulmonary TB and extrapulmonary TB. Among children with confirmed TB, microbiologic 
confirmation was required from >1 site; diagnosis of other sites of disease was based on the definitions of highly probable TB (online Technical Appendix 
Table 1, https://wwwnc.cdc.gov/EID/article/24/3/17-0785-Techapp1.pdf). 
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retrospectively applying more recent consensus definitions 
for research (26). Even after inclusion of all TB cases, our 
measure remained among the lowest, suggesting that many 
published clinical definitions would overdiagnose TB in 
this and similar settings were they to be applied routinely 
in clinical practice. The huge range in incidence estimates 
derived using different case definitions emphasizes the dif-
ficulty in interpreting existing disease burden data and the 
need for high-quality prospective incidence studies to im-
prove disease burden estimates.
Robust community incidence estimates depend on 
high-quality diagnosis to minimize misclassification as 
well as a high CDR. Broad screening criteria for all chil-
dren admitted to hospital with any features of suspected 
TB, plus active case detection through contact tracing, en-
sured that case ascertainment at KCH was optimized. Nev-
ertheless, the social, financial, and geographic barriers to 
obtaining hospital care in this setting mean that many ill 
KHDSS-resident children are not seen at KCH (18–20). 
Furthermore, challenges in childhood TB diagnosis, com-
bined with limited diagnostic resources, make surveillance 
data from other health facilities unreliable. We therefore 
estimated the CDR of hospital-based surveillance at KCH 
by using 3 independent techniques. Each measure is neces-
sarily a surrogate, and each has limitations, but the similar-
ity of these estimates supports their validity.
Because we used the highest CDR estimate to gener-
ate conservative estimates of childhood TB incidence, the 
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Table 2. Crude hospital-based childhood TB incidence, by age group and diagnostic classification, Kilifi Health and Demographic 
Surveillance Survey, Kenya, August 2009–July 2011* 
TB classification Age group, y 
No. person-years of 
observation 
No. KHDSS-resident 
TB cases 
Incidence, cases/100,000 
children/y (95% CI) 
Confirmed TB 0–4 89,503 7 7.8 (3.1–16.1) 
5–9 79,170 6 7.6 (2.8–16.5) 
10–14 70,073 2 2.9 (0.3–10.3) 
Total 238,746 15 6.3 (3.5–10.4) 
Confirmed or highly probable TB 0–4 89,503 30 33.5 (22.6–47.9) 
5–9 79,170 11 13.9 (6.9–24.9) 
10–14 70,073 3 4.3 (0.9–12.5) 
Total 238,746 44 18.4 (13.4–24.7) 
All TB 0–4 89,503 46 51.4 (37.6–68.6) 
5–9 79,170 21 26.5 (16.4–40.6) 
10–14 70,073 5 7.1 (2.3–16.7) 
Total 238,746 72 30.2 (23.6–38.0) 
*KDHSS, Kilifi Health and Demographic Surveillance Survey; TB, tuberculosis. 
 
 
Table 3. Incidence of childhood TB derived by applying other published clinical definitions, algorithms, and guidelines, in order of 
increasing incidence, Kilifi Health and Demographic Surveillance Survey, Kenya, August 2009–July 2011* 
Author, year (reference) Outcomes defined No. cases 
Incidence, cases/100,000 
children/y (95% CI)† 
WHO, 2006 (27) (a) Strongly suggestive of TB‡ 7 2.9 (1.2–6.0) 
Stegen (28) (a) Probable TB 18 7.5 (4.5–11.9) 
Nair (29) (a) “TB appears unquestionable” 28 11.7 (7.8–17.0) 
WHO, 2006 (27) (b) Requires investigation for TB‡ 33 13.8 (9.5–19.4) 
Graham (26) Probable TB 42 17.6 (12.7–23.8) 
Hawkridge (30) Probable TB 54 22.6 (17.0–29.5) 
Nair (29) (b) TB probable or “unquestionable” 55 23.0 (17.4–30.0) 
Stoltz (31) Probable TB 73 30.6 (24.0–38.5) 
Jeena (32) Probable TB 107 44.8 (36.7–54.2) 
Edwards (33) Criteria for TB treatment 110 46.1 (37.9–55.5) 
Ghidey (34) (a) Criteria for TB treatment§ 113 47.3 (39.0–56.9) 
WHO, 1983 (35) Probable TB 116 48.6 (40.2–58.3) 
Ramachandran (36) Criteria for TB treatment 118 49.4 (40.9–59.2) 
Ghidey (34) (b) Criteria for TB treatment§ 130 54.5 (45.4–64.7) 
Stegen (28) (b) Probable or possible TB 136 57.0 (47.8–67.4) 
Graham (26) Probable or possible TB 145 60.7 (51.3–71.5) 
Osborne (37) Probable TB 159 66.6 (56.7–77.8) 
Fourie (38) High probability of TB¶ 162 67.9 (57.8–79.2) 
Cundall (39) Probable TB 207 86.7 (75.3–99.4) 
Kiwanuka (40) Probable TB 219 91.7 (80.0–104.7) 
*TB, tuberculosis; WHO, World Health Organization. 
†Denominator for incidence calculations is the total person-years observation among children age <15 y (N = 238,746). 
‡Results shown separately for (a) children whose clinical features “strongly suggest a diagnosis of TB” according to the guidelines, and (b) using broader 
criteria that included under “physical signs highly suggestive of TB” all the other “suggestive clinical signs” listed as requiring investigation for TB. 
§Results for Ghidey and Habte tool (34) shown using both (a) >3 and (b) >2 signs and symptoms to define a “suggestive symptom complex of TB” (online 
Technical Appendix Table 1, https://wwwnc.cdc.gov/EID/article/24/3/17-0785-Techapp1.pdf). 
¶For the purposes of our analyses, we used “score 2” proposed by Fourie et al (38), which was derived in high TB burden settings in South Africa, 
Madagascar, and Nicaragua. 
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projected national incidence was 3 times higher than that re-
ported. Nevertheless, the projected ratio of adult-to-child TB 
cases is still consistent with other studies in Africa (43,44) 
and with recent global estimates (1,5,6,9), although lower 
than some regional and global figures (3). Other estimates 
of the global TB burden have indicated a lower proportion of 
childhood cases (7,8). However, in the absence of data from 
children, those estimates assume a similar CDR for adults 
(8) or impute missing data based on reported proportions of 
smear-negative and extrapulmonary TB by age group (7), as-
sumptions that have been challenged (11,45). Our study pro-
vides important empirical data on the probable CDR among 
children. The results suggest that the CDR among children is 
substantially lower than among adults and support estimates 
derived using other modeling approaches (5,6), including re-
cently revised WHO estimates of global childhood TB inci-
dence that assume a CDR of 36% (9).
The strong association of childhood TB with a history 
of close TB contact has 2 important implications for clinical 
practice and public health policy. First, eliciting a history 
of TB contact should be a standard part of the assessment 
of every ill child in TB-endemic settings. Among inpatients 
in our study, 1 in 5 with a known close TB contact had 
CHPTB. Early identification and investigation of this high-
risk group might improve clinical outcomes through earlier 
diagnosis and treatment.
Second, and most important, our finding that 49% TB 
cases among children <5 years of age were attributable to a 
known household TB contact suggests that half the CHPTB 
cases in young children might have been prevented by 
chemoprophylaxis. Estimating the population attributable 
fraction of contact with a person with confirmed TB pro-
vides a novel approach for assessing the potential impact 
of TB chemoprophylaxis at the population level that might 
be applied to other settings. Our results from Kenya sup-
port recent global estimates of TB burden among child TB 
contacts (25). By demonstrating a large potential impact 
on childhood TB incidence, our findings provide further 
strong endorsement for existing policy recommendations 
for TB chemoprophylaxis (25,46).
Extrapolation of results from a single district must be 
interpreted with caution. Childhood TB incidence and the 
contribution of childhood TB cases to the total TB burden 
are likely to be affected by factors that vary geographically, 
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Table 4. Case detection rate estimates derived by using TB notifications, Kilifi Health and Demographic Surveillance Survey census 
data, and verbal autopsy methods, Kenya, August 2009–July 2011* 
Method Calculation of CDR estimate 
CDR 
estimate 
(95% CI) 
TB notifications 
 Passive case  
 detection 
No. KHDSS-resident smear-positive child TB cases captured by KIDS TB Study
Total no. KHDSS-resident smear-positive child TB cases =  
3
10 
0.30  
(0.07–0.65) 
 Active contact  
 tracing 
No. index cases captured at KCH
Total no. index cases 
No. eligible child contacts investigated
Total no. eligible child contacts identified at KCH =  
195
362   
108
297 
0.20  
(0.13–0.26) 
KHDSS census 
 Mortality  
 surveillance 
No. KHDSS-resident children who died at KCH
Total no. childhood deaths among KHDSS residents =
182
514 
0.35  
(0.31–0.40) 
Verbal autopsy 
 TB deaths No. TB deaths in VA study that occurred in children captured by KIDS TB Study 
No. TB deaths in VA study =
2
10 
0.20  
(0.03– 0.56) 
 TB suspected  
 deaths 
No. TB suspected deaths in VA study that were captured by KIDS TB Study 
No. TB suspected deaths in VA study =
x
y 
0.22  
(0.15–0.32) 
*CDR, case detection rate; KCH, Kilifi County Hospital; KHDSS, Kilifi Health and Demographic Surveillance Survey; TB, tuberculosis, VA, verbal autopsy. 
 
 
Table 5. Estimated annual caseload and incidence of childhood TB after adjustment for the case detection rate, Kilifi Health and 
Demographic Surveillance Survey, August 2009–July 2011* 
TB classification Age group, y No. cases Adjusted incidence, cases/100,000 children/y (95% CI) 
Confirmed TB 0–4 20 22 (9–46) 
5–9 17 22 (8–47) 
10–14 6 9 (1–29) 
Total 43 18 (10–30) 
Confirmed or highly probable TB 0–4 86 96 (65–137) 
5–9 31 39 (20–71) 
10–14 9 13 (3–36) 
Total 126 53 (38–71) 
All TB 0–4 131 146 (107–196) 
5–9 60 76 (47–116) 
10–14 14 20 (7–48) 
Total 205 86 (67–109) 
*To generate the most conservative estimates of community childhood TB incidence, we used the highest case detection rate estimate of 0.35 derived 
from hospital-based mortality surveillance. TB, tuberculosis. 
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including community TB prevalence; social and demo-
graphic factors, such as urbanization, that affect the annual 
risk for TB infection; prevalence of host factors, such as 
BCG vaccination, HIV infection, and malnutrition; and 
local population structures. Therefore, we did not attempt 
simply to age-standardize the Kilifi incidence rates to the 
national population of children in Kenya.
We reasoned instead that the proportion of the total 
TB caseload accounted for by children is probably less 
prone to geographic variation, and estimated the national 
burden of childhood TB by assuming that the CDR among 
adults and the ratio of adult-to-child cases is the same in the 
KHDSS and nationally. Importantly, the age structures of 
the KHDSS and Kenya are very similar (13,24), suggesting 
that age is unlikely to confound this approach. Compared 
with Kilifi, the higher estimate of TB incidence nationally 
is consistent with greater urbanization (13,24) and a higher 
annual risk for TB infection (47), HIV prevalence (24), 
and overall TB incidence (1). Because ecologic data sug-
gest that the pediatric proportion of cases actually increases 
with increasing overall TB incidence (6,12), this approach 
might underestimate the actual national childhood TB 
burden. Our restriction of TB cases to those that met the 
stringent criteria of CHPTB and our adjustment of hospital-
based incidence rates using the highest CDR estimate also 
suggest that our estimates are conservative.
In conclusion, by using a combination of clinical, 
laboratory, and epidemiologic resources not usually avail-
able for routine surveillance, we have estimated the inci-
dence of childhood TB in Kenya. Although this study is 
very resource-intensive, the wide range of incidence esti-
mates based on existing clinical definitions highlights the 
difficulty in interpreting routine notification data and rein-
forces the need for similar studies in a range of different 
epidemiologic settings. In a setting where routine facilities 
for childhood TB diagnosis are typical of most countries 
with a high TB burden, our results also provide important 
empirical data on the TB CDR among children. The re-
sults support recently improved WHO estimates of global 
childhood TB incidence based on modeling approaches, 
which assume a very similar CDR (1,9). Our findings also 
reinforce the urgent need to improve case detection among 
children to reduce childhood TB mortality (48). Crucially, 
they suggest that half the TB cases in young children might 
be prevented by implementing existing WHO guidelines 
for contact tracing and chemoprophylaxis.
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Table 6. Crude and adjusted odds ratios for risk factors associated with confirmed or highly probable TB among children examined at 
Kilifi County Hospital and Coast Provincial General Hospital, Kenya, August 2009–July 2011* 
Age group 
Cases 
 
Controls 
Crude OR for TB 
(95% CI) p value 
aOR for TB 
(95% CI) p value 
Factor 
present 
Factor 
absent 
Factor 
present 
Factor 
absent 
Children <5 y          
 HIV infection† 17 73  112 872 1.8 (1.0–3.2) 0.036 1.3 (0.7–2.4) 0.321 
 Severe malnutrition‡ 56 35  413 620 2.4 (1.5–3.7) <0.001 2.6 (1.6–4.1) <0.001 
 BCG vaccination scar 82 9  921 112 1.1 (0.5–2.3) 0.779 –  
 Close TB contact 33 58  125 908 4.1 (2.6–6.6) <0.001 5.1 (3.1–8.3) <0.001 
Children 5–14 y            
 HIV infection† 21 38  47 143 1.7 (0.9–3.2) 0.103 1.5 (0.8–2.9) 0.229 
 Severe malnutrition‡ 9 50  43 157 0.7 (0.3–1.4) 0.294 –  
 BCG vaccination scar 48 11  173 27 0.7 (0.3–1.5) 0.327 –  
 Close TB contact 30 29  34 166 5.1 (2.6–9.9) <0.001 5.2 (2.7–9.8) <0.001 
All children <15 y            
 HIV infection† 38 111  159 1,015 2.2 (1.5–3.3) <0.001 1.9 (1.2–2.9) 0.003 
 Severe malnutrition‡ 65 85  456 777 1.3 (0.9–1.8) 0.130 –  
 BCG vaccination scar 130 20  1,094 139 0.8 (0.5–1.4) 0.455 –  
 Close TB contact 63 87  159 1,074 5.0 (3.4–7.3) <0.001 5.0 (3.4–7.2) <0.001 
*aOR, adjusted odds ratio; BCG, bacillus Calmette-Guérin; OR, odds ratio; TB, tuberculosis. 
†HIV status was missing for 1/150 (0.7%) cases and 59/1233 (4.8%) controls. 
‡Severe malnutrition defined according to World Health Organization guidelines as weight-for-age z-score of <3 or the presence of nutritional edema (42). 
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